Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 45 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Laleman Pharma from Diksmuide, company number BE1010156713, closed financial year 2025 with a result of € -37,832 after tax. For that financial year Laleman Pharma recorded a gross margin of € 232,565 and equity of € 212,168. The company made a loss. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 8, 2026.
€ 212,168
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -37,832
Profit after tax over the fiscal year.
€ 122,538
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -37,832.
People and assets in 2025
0.1
Average over the fiscal year, from the social balance sheet.
€ 12,864
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 906,414
€ 53,462 is repaid this year. At this pace the long-term loan is gone in ≈ 17 years.
€ 28,073
Supplier invoices still open on the last day of the fiscal year.
€ 11,827
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
What happened to Laleman Pharma?
What happened at Laleman Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 37,832. Source: NBB ↗
- New establishment in Diksmuide. KBO
- Merel Laleman became a director. NBB
- Start of the company according to the CBE. KBO
A new publication or filing at Laleman Pharma? We notify you, reason included.
Follow Laleman PharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Laleman Pharma is Merel Laleman.
Directors
According to the 2025 annual accounts
Merel Laleman
Director
since 2024
Establishments
Establishment units
Physical locations of this company
Esenweg 232
8600 Diksmuide
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1010.156.713
- VAT number
- BE 1010.156.713
- Registered office
- Esenweg 232, 8600 Diksmuide
- Names & denominations
- Laleman Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 7 June 2024
- Peppol
- Active · Active since 16 Jun 2025
- Activities · NACE
Detailhandel in farmaceutische producten